Raphael Pharmaceutical (RAPH) Research & Development (2020 - 2026)
Raphael Pharmaceutical's Research & Development came in at $40,000 for Q2 2026, down 71.6% from $141,000 a year earlier.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Research & Development (2020 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Raphael Pharmaceutical reported Research & Development of $554,000, up 3.0% year-over-year; for FY2025, it was $631,000, down 18.7% from FY2024.
- Research & Development carries a five-year compound annual growth rate of 6.5% (FY2020 to FY2025).
- Going back by year, Research & Development was $776,000 in FY2024 (+36.4%), $569,000 in FY2023 (-51.7%), $1.18 million in FY2022 (+51.8%) and $776,000 in FY2021 (+68.3%).
- The Q2 2026 figure represents the lowest quarterly Research & Development since Q2 2024.
- The fastest year-over-year change in Research & Development over five years came in Q2 2025 (growth of 487.5%), and the weakest in Q2 2024 (a decline of 91.8%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Raphael Pharmaceutical | 30.47 Mn | 30.40 Mn | - | 40,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40,000.00 |
| Jun 30, 2025 | 141,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 24,000.00 |
| Mar 31, 2024 | 379,000.00 |
| Dec 31, 2023 | -348,000.00 |
| Sep 30, 2023 | 510,000.00 |
| Jun 30, 2023 | 293,000.00 |
| Mar 31, 2023 | 114,000.00 |
| Dec 31, 2022 | 676,000.00 |
| Sep 30, 2022 | 332,000.00 |
| Jun 30, 2022 | 84,000.00 |
| Mar 31, 2022 | 86,000.00 |
| Dec 31, 2021 | 224,000.00 |
| Sep 30, 2021 | 161,000.00 |
| Jun 30, 2021 | 222,000.00 |
| Mar 31, 2021 | 169,000.00 |
| Dec 31, 2020 | 220,000.00 |
| Sep 30, 2020 | 69,000.00 |
API Access
Raphael Pharmaceutical Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=RAPH&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "RAPH", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=RAPH&period=max&api_key=YOUR_API_KEY");
const data = await res.json();